Relapsed/Refractory B-cell Malignancies Clinical Trial
Official title:
A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Malignancy Activity of AC676 in Patients With Relapsed/Refractory B-cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: - Identify the recommended dose of AC676 that can be given safely to participants - Evaluate the safety profile of AC676 - Evaluate the pharmacokinetics of AC676 - Evaluate the effectiveness of AC676
AC676-001 is a Phase I, first-in-human, open-label, multi-center dose-escalation study of AC676 given as a single agent. AC676 is an investigational medicinal product that is an orally bioavailable BTK degrader for the treatment of B-cell malignancies. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02457559 -
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT04943016 -
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04689308 -
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04861779 -
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
|
Phase 1 |